Sac-TMT extended survival and improved response rates vs chemotherapy in endometrial cancer that had progressed after chemotherapy and immunotherapy.

Single-agent pembrolizumab extended progression-free survival vs carboplatin and paclitaxel in mismatch repair–deficient endometrial cancer.

Adding pembrolizumab to adjuvant radiation did not meet prespecified superiority criteria in patients with stage I/II high-intermediate–risk dMMR endometrioid endometrial cancer in the phase 3 NRG-GY020 trial.

Interim DUO-E data showed longer median survival with chemotherapy plus durvalumab and olaparib maintenance that did not reach significance.

See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.

First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.

The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.

IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.